{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:52:36Z","timestamp":1784591556099,"version":"3.55.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To investigate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A manual search was conducted in 3 prestigious English databases, Cochrane Library, PubMed, and Web of Science, for studies published within the last decade, from July 2014 to July 2024. The extracted literature was synthesized to analyze the efficacy outcomes, survival prognostic indicators, and safety profiles of SGLT-2 inhibitors in patients with HF and T2DM. The Cochrane bias risk assessment scale was used as a tool to evaluate the quality of the literature, and Review Manager 5.4 software was used to create the bias risk chart. Data analysis and merging were completed with the help of Review Manager 5.4 and Stata 15.0 statistical software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twelve studies encompassing 9509 patients were included in the meta-analysis. The results revealed that compared to the control group, the SGLT-2 inhibitor-treated group demonstrated significantly greater reductions in left ventricular end-diastolic volume index [mean difference (MD)\u2005=\u2005-7.25, 95% confidence intervals [95% CI] (-9.83, -4.67)], brain natriuretic peptide levels [MD\u2005=\u2005-36.96, 95% CI (-63.51, -10.41)], and N-terminal pro-brain natriuretic peptide [MD\u2005=\u2005-519.27, 95% CI (-660.77, -377.78)]. Furthermore, the SGLT-2 inhibitor-treated group exhibited significantly higher increases in Kansas City Cardiomyopathy Questionnaire scores [MD\u2005=\u20053.32, 95% CI (3.30, 3.34)], indicating improved quality of life. Additionally, the incidence of adverse events was significantly lower in the SGLT-2 inhibitor-treated group compared to the control group [OR\u2005=\u20050.78, 95% CI (0.69, 0.88)]. The pooled results of the meta-analysis indicated that SGLT-2 inhibitor therapy reduced the risk of cardiovascular death or HF hospitalization by 23%, the risk of cardiovascular death by 19%, and the risk of all-cause mortality by 9%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>SGLT-2 inhibitor therapy significantly reduced the risks of all-cause mortality, cardiovascular death, and hospitalization for HF in patients with HF and T2DM. Additionally, SGLT-2 inhibitors significantly improve cardiac function, decrease the incidence of adverse events, and enhance the quality of life in these patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042196","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T22:52:49Z","timestamp":1746485569000},"page":"e42196","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Meta-analysis of the efficacy and safety of SGLT-2 inhibitors in patients with heart failure and type 2 diabetes mellitus"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0816-3576","authenticated-orcid":false,"given":"Xinliang","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Cardiology, Huaihe Hospital of Henan University, Gulou District, Kaifeng, Henan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huaihe Hospital of Henan University, Gulou District, Kaifeng, Henan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huaihe Hospital of Henan University, Gulou District, Kaifeng, Henan Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250513","doi-asserted-by":"crossref","first-page":"1373314","DOI":"10.3389\/fphar.2024.1373314","article-title":"Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R2-20250513","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-024-02294-z","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.","volume":"23","author":"Wang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"R3-20250513","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1111\/dom.15572","article-title":"Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: an EMPEROR-Pooled analysis.","volume":"26","author":"Talha","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R4-20250513","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/dom.15340","article-title":"Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial.","volume":"26","author":"Sharma","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R5-20250513","doi-asserted-by":"crossref","first-page":"57","DOI":"10.25122\/jml-2023-0340","article-title":"The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes.","volume":"17","author":"Sabbar","year":"2024","journal-title":"J Med Life"},{"key":"R6-20250513","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s11658-024-00536-2","article-title":"New insights into the role of mitochondrial metabolic dysregulation and immune infiltration in septic cardiomyopathy by integrated bioinformatics analysis and experimental validation.","volume":"29","author":"Li","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"R7-20250513","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00204-023-03599-w","article-title":"Involvement of mitochondrial dynamics and mitophagy in diabetic endothelial dysfunction and cardiac microvascular injury.","volume":"97","author":"Zhang","year":"2023","journal-title":"Arch Toxicol"},{"key":"R8-20250513","doi-asserted-by":"crossref","first-page":"154502","DOI":"10.1016\/j.phymed.2022.154502","article-title":"\u00df-tubulin contributes to Tongyang Huoxue decoction-induced protection against hypoxia\/reoxygenation-induced injury of sinoatrial node cells through SIRT1-mediated regulation of mitochondrial quality surveillance.","volume":"108","author":"Chang","year":"2023","journal-title":"Phytomedicine"},{"key":"R9-20250513","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.2147\/IDR.S375694","article-title":"Linezolid-induced pancytopenia in patients using dapagliflozin: a case series.","volume":"15","author":"Li","year":"2022","journal-title":"Infect Drug Resist"},{"key":"R10-20250513","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/cpt.3194","article-title":"SGLT-2 inhibitor use and cause-specific hospitalization rates: an outcome-wide study to identify novel associations of SGLT-2 inhibitors.","volume":"115","author":"Tan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20250513","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3949\/ccjm.91c.04001","article-title":"When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?","volume":"91","author":"Sharma","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"R12-20250513","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3949\/ccjm.91c.02001","article-title":"Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?","volume":"91","author":"Modarressi","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"R13-20250513","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-023-01877-6","article-title":"Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.","volume":"22","author":"Sohn","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"R14-20250513","doi-asserted-by":"crossref","first-page":"100477","DOI":"10.1016\/j.ajpc.2023.100477","article-title":"Call to action: understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.","volume":"13","author":"Khedagi","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"R15-20250513","doi-asserted-by":"crossref","first-page":"393","DOI":"10.36290\/vnl.2022.080","article-title":"SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction.","volume":"68","author":"Sliva","year":"2022","journal-title":"Vnitr Lek"},{"key":"R16-20250513","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R17-20250513","doi-asserted-by":"crossref","first-page":"426","DOI":"10.7150\/ijbs.76223","article-title":"Molecular mechanisms of mitochondrial quality control in ischemic cardiomyopathy.","volume":"19","author":"Chang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"R18-20250513","doi-asserted-by":"crossref","first-page":"155331","DOI":"10.1016\/j.phymed.2023.155331","article-title":"Zishenhuoxue decoction-induced myocardial protection against ischemic injury through TMBIM6-VDAC1-mediated regulation of calcium homeostasis and mitochondrial quality surveillance.","volume":"132","author":"Chang","year":"2024","journal-title":"Phytomedicine"},{"key":"R19-20250513","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/ptr.8177","article-title":"Quercetin inhibits necroptosis in cardiomyocytes after ischemia-reperfusion via DNA-PKcs-SIRT5-orchestrated mitochondrial quality control.","volume":"38","author":"Chang","year":"2024","journal-title":"Phytother Res"},{"key":"R20-20250513","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/00015385.2023.2240130","article-title":"Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction.","volume":"79","author":"Afshani","year":"2024","journal-title":"Acta Cardiol"},{"key":"R21-20250513","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial.","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"R22-20250513","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"R23-20250513","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF).","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"R24-20250513","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"R25-20250513","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program.","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation"},{"key":"R26-20250513","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","article-title":"Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: results from the CREDENCE trial.","volume":"233","author":"Sarraju","year":"2021","journal-title":"Am Heart J"},{"key":"R27-20250513","doi-asserted-by":"crossref","first-page":"e007048","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study.","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R28-20250513","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12933-022-01589-3","article-title":"Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.","volume":"21","author":"Tanaka","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R29-20250513","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1253\/circrep.CR-21-0030","article-title":"Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes.","volume":"3","author":"Ueda","year":"2021","journal-title":"Circ Rep"},{"key":"R30-20250513","first-page":"1778","article-title":"Association between dapagliflozin, cardiac biomarkers and cardiac remodeling in patients with diabetes mellitus and heart failure.","volume":"13","author":"Xanthopoulos","year":"2023","journal-title":"Life (Basel)"},{"key":"R31-20250513","doi-asserted-by":"crossref","first-page":"102334","DOI":"10.1016\/j.eclinm.2023.102334","article-title":"DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial.","volume":"66","author":"Yoshihara","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R32-20250513","first-page":"61","article-title":"An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors.","volume":"25","author":"Kilickap","year":"2021","journal-title":"Anatol J Cardiol"},{"key":"R33-20250513","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11886-021-01486-3","article-title":"SGLT-2 inhibitors in heart failure: guide for prescribing and future perspectives.","volume":"23","author":"Garla","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"R34-20250513","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2019.11.009","article-title":"How do SGLT-2 inhibitors work to prevent heart failure?","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R35-20250513","first-page":"224","article-title":"Novel oral hypoglycemic agents SGLT-2 inhibitors: cardiovascular benefits and potential mechanisms.","volume":"75","author":"Li","year":"2020","journal-title":"Pharmazie"},{"key":"R36-20250513","doi-asserted-by":"crossref","first-page":"e029058","DOI":"10.1161\/JAHA.122.029058","article-title":"Association of SGLT-2 inhibitors with treatment satisfaction and diabetes-specific and general health status in adults with cardiovascular disease and type 2 diabetes.","volume":"12","author":"Ding","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R37-20250513","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cardfail.2021.11.010","article-title":"Projected clinical benefits of implementation of SGLT-2 inhibitors among medicare beneficiaries hospitalized for heart failure.","volume":"28","author":"Vaduganathan","year":"2022","journal-title":"J Card Fail"},{"key":"R38-20250513","doi-asserted-by":"crossref","first-page":"1081920","DOI":"10.3389\/fphys.2022.1081920","article-title":"The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: a systematic review and meta-analysis.","volume":"13","author":"Peng","year":"2022","journal-title":"Front Physiol"},{"key":"R39-20250513","doi-asserted-by":"crossref","first-page":"12325","DOI":"10.3390\/ijms232012325","article-title":"Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms.","volume":"23","author":"La Grotta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R40-20250513","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives.","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R41-20250513","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1753-0407.13182","article-title":"Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?","volume":"13","author":"Singh","year":"2021","journal-title":"J Diabetes"},{"key":"R42-20250513","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejim.2021.02.009","article-title":"Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction.","volume":"87","author":"Patoulias","year":"2021","journal-title":"Eur J Intern Med"},{"key":"R43-20250513","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12933-021-01400-9","article-title":"GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R44-20250513","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000504694","article-title":"SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone?","volume":"145","author":"Santos-Ferreira","year":"2020","journal-title":"Cardiology"},{"issue":"Suppl 2","key":"R45-20250513","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/dom.13692","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors: do we need them for glucose-lowering, for cardiorenal protection or both?","volume":"21","author":"Scholtes","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R46-20250513","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","article-title":"Do the SGLT-2 inhibitors offer more than hypoglycemic activity?","volume":"32","author":"Flores","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"R47-20250513","first-page":"197","article-title":"Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.","volume":"23","author":"Wang","year":"2024","journal-title":"Res Sq"},{"key":"R48-20250513","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12933-024-02174-6","article-title":"The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.","volume":"23","author":"Vercalsteren","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"R49-20250513","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/08445621241253124","article-title":"Addressing Culturally Based Hidden Bias and RacisM (A-CHARM) using simulation experiences, Nik\u2019s story: a quasi-experimental study.","volume":"57","author":"Sawhney","year":"2024","journal-title":"Can J Nurs Res"},{"key":"R50-20250513","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/dom.14626","article-title":"The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.","volume":"24","author":"Kaku","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R51-20250513","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.arbres.2024.04.028","article-title":"Chronic cough and cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS): screening for mutations in replication factor C subunit 1 (RFC1).","volume":"60","author":"Palones","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"R52-20250513","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 Trial.","volume":"45","author":"Mosenzon","year":"2022","journal-title":"Diabetes Care"},{"key":"R53-20250513","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacasi.2022.02.004","article-title":"Effects of dapagliflozin in asian patients with heart failure and reduced ejection fraction in DAPA-HF.","volume":"2","author":"Docherty","year":"2022","journal-title":"JACC Asia"},{"key":"R54-20250513","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14779072.2024.2324027","article-title":"A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials.","volume":"22","author":"Garcia-Moll","year":"2024","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R55-20250513","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/dc23-1450","article-title":"Impact of canagliflozin on kidney and cardiovascular outcomes by type 2 diabetes duration: a pooled analysis of the CANVAS program and CREDENCE trials.","volume":"47","author":"Tobe","year":"2024","journal-title":"Diabetes Care"},{"key":"R56-20250513","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13300-024-01571-0","article-title":"Effect of luseogliflozin on myocardial flow reserve in patients with type 2 diabetes mellitus (LUCENT-J Study).","volume":"15","author":"Tamanaha","year":"2024","journal-title":"Diabetes Ther"},{"key":"R57-20250513","doi-asserted-by":"crossref","first-page":"117371","DOI":"10.1016\/j.jep.2023.117371","article-title":"Zishen Tongyang Huoxue decoction (TYHX) alleviates sinoatrial node cell ischemia\/reperfusion injury by directing mitochondrial quality control via the VDAC1-beta-tubulin signaling axis.","volume":"320","author":"Chang","year":"2024","journal-title":"J Ethnopharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:06:18Z","timestamp":1747173978000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":57,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042196","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}